FY2025 EPS Estimates for TSE:MDP Raised by Leede Financial

Medexus Pharmaceuticals Inc. (TSE:MDP) – Investment analysts at Leede Financial raised their FY2025 earnings estimates for Medexus Pharmaceuticals in a research note issued on Monday, December 2nd. Leede Financial analyst D. Loe now anticipates that the company will post earnings of $0.20 per share for the year, up from their previous estimate of $0.19. Leede Financial has a “Speculative Buy” rating and a $8.25 price target on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

Several other equities research analysts have also issued reports on MDP. Stifel Nicolaus lifted their price objective on Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Raymond James upgraded Medexus Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the company from C$3.00 to C$4.00 in a research report on Wednesday, November 20th. Finally, Stifel Canada upgraded shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Monday, August 12th. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of C$5.25.

Medexus Pharmaceuticals Price Performance

Shares of TSE:MDP opened at C$2.84 on Wednesday. The company has a market cap of C$69.67 million, a price-to-earnings ratio of 56.80 and a beta of 1.96. Medexus Pharmaceuticals has a one year low of C$1.47 and a one year high of C$3.16. The firm has a fifty day moving average price of C$2.48 and a two-hundred day moving average price of C$2.26.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.